First American Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

First American Trust’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-28,323	Closed	-$3.97M	–	127
2017 Q3	$3.97M	Buy	28,323 +998	+4%	+$136K	1.04%	35
2017 Q2	$3.32M	Buy	27,325 +2,745	+11%	+$319K	0.92%	44
2017 Q1	$2.98M	Buy	+24,580	New	+$3.17M	0.91%	48

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

First American Trust's ALXN Position: Q4 2017 in Review

First American Trust sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 28,323 shares — an estimated $3.97M sold.

First American Trust first reported a position in ALXN in Q1 2017 and held it in 3 quarters. The position peaked at $3.97M in Q3 2017. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

First American Trust reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
First American Trust sold 28,323 Alexion Pharmaceuticals shares in Q4 2017, an estimated $3.97M.
First American Trust first reported a position in Alexion Pharmaceuticals in Q1 2017 and held it in 3 quarters.
First American Trust's Alexion Pharmaceuticals position peaked at $3.97M in Q3 2017.
587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on First American Trust's 13F filing for Q4 2017, filed 11 Jan 2018.